Drug Trial Radar · NCT01049425
Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer
Last checked: Nov 19, 2026Latest source record: Aug 14, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,198
Actual
Start
Feb 5, 2009
Primary completion
Mar 1, 2017
Study completion May 15, 2018
Sponsor
- Lead sponsor
- Women's Cancer Study Group GmbHAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sanofi; Amgen
- First posted
- Jan 14, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The planned trial compares an anthracycline-free taxane based regimen versus a modern third generation (anthracycline/taxane-based) regimen in HER2/neu non-over expressing tumors. The aim is to define a further anthracycline-free standard and to spare anthracycline toxicity to a patient, who will only have a modest benefit from this compound. Prior to randomization for chemotherapy for all patients with HR positive disease OncotypeDX® will be performed to identify patients who should not receive chemotherapy. Secondary objectives of this trial will be to compare overall survival and toxicity between the two chemotherapy arms, to evaluate survival in the observation arm and to perform translational research regarding prognostic and predictive factors.
Conditions
- Primary Breast Cancer
- Her2 Non-overexpressing
Interventions
EpirubicinDrug
4 cycles, intravenous use, day 1 every three weeks
CyclophosphamideDrug
4 cycles, intravenous infusion, day 1 every three weeks
DocetaxelDrug
4 cycles, intravenous infusion, day 1 every three weeks after completion of EC-chemotherapy
CyclophosphamideDrug
6 cycles, intravenous infusion, day 1 every 3 weeks
DocetaxelDrug
6 cycles, intravenous infusion, day one every three weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- disease-free survival in patients treated with either 6 cycles of Docetaxel / Cyclophosphamide chemotherapy or 4 cycles of EC followed by 4 cycles of Docetaxel as adjuvant treatmentTime frame: 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bethesda Krankenhaus
Mönchengladbach, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.